Literature DB >> 3810836

Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity.

T M Coffman, D R Carr, W E Yarger, P E Klotman.   

Abstract

Previous reports suggest that cyclosporine (CsA) may have direct effects on arachidonic acid (AA) metabolism in several different tissues. However, the effects of CsA on renal eicosanoid production are unclear. Furthermore, the potential role of changes in renal prostaglandin and thromboxane metabolism in mediating CsA nephrotoxicity is not known. Therefore, in this study, we evaluated the effects of CsA toxicity on the production of AA metabolites by the kidney. In a postischemic, denervated rat model, CsA (50 mg/kg/day) administered for 12-14 days resulted in significant nephrotoxicity with marked decreases in both glomerular filtration rate and renal blood flow. This reduction in renal function was associated with an increase in the renal production of TXB2, PGE2, and 6-PGF1 alpha in vitro. Arachidonic acid significantly stimulated renal eicosanoid production above control values. Increased urinary excretion of TXB2, 2,3-dinorTXB2 (a major TXB2 metabolite), and 6-keto-PGF1 alpha also occurred in rats with CsA nephrotoxicity and reflected the increase in renal production of these eicosanoid products. In contrast, urinary PGE2 excretion was not increased in CsA toxic rats. Thus, CsA nephrotoxicity is associated with specific alterations in renal AA metabolism. Furthermore, alterations in AA metabolism may be important in modulating renal hemodynamics and excretory function in this model. These studies suggest that specific inhibition of vasoconstrictor products of AA metabolism might ameliorate the nephrotoxic effects of CsA.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3810836     DOI: 10.1097/00007890-198702000-00023

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

Review 1.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 2.  The cyclosporins.

Authors:  Z Rehácek
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

Review 3.  Current status of renal transplantation.

Authors:  M G Suranyi; B M Hall
Journal:  West J Med       Date:  1990-06

Review 4.  Cyclosporin-induced hypertension: incidence, pathogenesis and management.

Authors:  S J Taler; S C Textor; V J Canzanello; L Schwartz
Journal:  Drug Saf       Date:  1999-05       Impact factor: 5.606

Review 5.  Renal dysfunction associated with liver transplantation.

Authors:  R M Jindal; I Popescu
Journal:  Postgrad Med J       Date:  1995-09       Impact factor: 2.401

6.  Cyclosporin therapy in vivo attenuates the response to vasodilators in the isolated perfused kidney of the rabbit.

Authors:  H S Cairns; L D Fairbanks; J Westwick; G H Neild
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

7.  Acute and chronic renal failure in liver transplantation.

Authors:  J McCauley; D H Van Thiel; T E Starzl; J B Puschett
Journal:  Nephron       Date:  1990       Impact factor: 2.847

Review 8.  Prevention and management of the adverse effects associated with immunosuppressive therapy.

Authors:  S J Rossi; T J Schroeder; S Hariharan; M R First
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

Review 9.  Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity.

Authors:  G R Matzke; R F Frye
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

10.  Interaction of dietary fatty acids and cyclosporine A in the borderline hypertensive rat: tissue fatty acids.

Authors:  D E Mills; R de Antueno; J Scholey
Journal:  Lipids       Date:  1994-01       Impact factor: 1.880

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.